IN2015DN03733A - - Google Patents
Info
- Publication number
- IN2015DN03733A IN2015DN03733A IN3733DEN2015A IN2015DN03733A IN 2015DN03733 A IN2015DN03733 A IN 2015DN03733A IN 3733DEN2015 A IN3733DEN2015 A IN 3733DEN2015A IN 2015DN03733 A IN2015DN03733 A IN 2015DN03733A
- Authority
- IN
- India
- Prior art keywords
- scaffold
- ester
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261725949P | 2012-11-13 | 2012-11-13 | |
| PCT/US2013/069686 WO2014078309A1 (en) | 2012-11-13 | 2013-11-12 | Cannabinoid receptor mediating compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03733A true IN2015DN03733A (enrdf_load_stackoverflow) | 2015-09-18 |
Family
ID=49725346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3733DEN2015 IN2015DN03733A (enrdf_load_stackoverflow) | 2012-11-13 | 2013-11-12 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US9765031B2 (enrdf_load_stackoverflow) |
| EP (1) | EP2919779B1 (enrdf_load_stackoverflow) |
| JP (1) | JP6272626B2 (enrdf_load_stackoverflow) |
| CN (1) | CN104884057B (enrdf_load_stackoverflow) |
| CA (1) | CA2889697C (enrdf_load_stackoverflow) |
| IN (1) | IN2015DN03733A (enrdf_load_stackoverflow) |
| WO (1) | WO2014078309A1 (enrdf_load_stackoverflow) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11155521B2 (en) * | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| US9765031B2 (en) * | 2012-11-13 | 2017-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| CN106660968B (zh) * | 2014-05-09 | 2020-02-07 | 美国政府(由卫生和人类服务部的部长所代表) | 吡唑衍生物及其作为大麻素受体介体的用途 |
| EP3303325A1 (en) * | 2015-06-04 | 2018-04-11 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cannabinoid receptor mediating compounds |
| EP3423448B1 (en) * | 2016-03-04 | 2024-12-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cannabinoid receptor mediating compounds |
| RU2703484C1 (ru) * | 2018-05-22 | 2019-10-17 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный аграрный университет имени Н.И. Вавилова" | Способ производства безоболочных колбасок для функционального питания |
| JP2023518529A (ja) * | 2020-03-24 | 2023-05-01 | インバースアゴ・ファーマ・インコーポレイテッド | 非晶質３，４－ジフェニル－４，５－ジヒドロ－１ｈ－ピラゾール誘導体の固体分散体、それを含む組成物及びカンナビノイドｃｂ１受容体阻害剤としてのその使用 |
| EP4132912A4 (en) * | 2020-04-07 | 2024-05-01 | Inversago Pharma Inc. | PROCESS FOR PRODUCING 4,5-DIHYDRO-1H-PYRAZOLES AND INTERMEDIATES |
| CN118829427A (zh) * | 2022-02-24 | 2024-10-22 | 诺和诺德股份有限公司 | 治疗腹型肥胖、高甘油三酯血症和/或血糖受损受试者的方法 |
| IL314385A (en) * | 2022-03-14 | 2024-09-01 | Us Health | Cannabinoid receptor modulating compounds |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| CA1236641A (en) | 1984-07-06 | 1988-05-10 | Motoaki Tanaka | Copolymer of lactic acid and glycolic acid and method for producing same |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| SI1268435T1 (sl) | 2000-03-23 | 2007-02-28 | Solvay Pharm Bv | 4,5-dihidro-1h-pirazolni derivati s cb 1-antagonisticno aktivnostjo |
| CN100366614C (zh) * | 2001-03-22 | 2008-02-06 | 索尔瓦药物有限公司 | 具有cb1－拮抗活性的4,5－二氢－1h－吡唑衍生物 |
| CA2442245C (en) | 2001-09-21 | 2010-03-30 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
| KR100903760B1 (ko) | 2001-09-21 | 2009-06-19 | 솔베이 파마슈티칼스 비. 브이 | Ｃｂ1-길항 작용을 가지는 신규한4,5-디하이드로-1ｈ-피라졸 유도체 |
| US20050239859A2 (en) * | 2003-09-03 | 2005-10-27 | Solvay Pharmaceuticals Gmbh | Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity |
| ATE402697T1 (de) | 2004-01-30 | 2008-08-15 | Solvay Pharm Bv | 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität |
| EP1574211A1 (en) | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| WO2006060192A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Pyrazole derivatives |
| EP2023920B1 (en) | 2006-05-05 | 2012-06-13 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists |
| US7655685B2 (en) | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| EA018900B1 (ru) | 2007-12-10 | 2013-11-29 | 7ТиЭм ФАРМА А/С | Соединения, модулирующие активность каннабиноидного рецептора св1, композиции на их основе и их применение |
| ES2540119T3 (es) | 2009-03-27 | 2015-07-08 | Abbvie Inc. | Compuestos como ligandos de receptores cannabinoides |
| US8217038B2 (en) | 2009-10-07 | 2012-07-10 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| JP5946192B2 (ja) | 2010-11-18 | 2016-07-05 | ジェンリン ディスカバリーＪｅｎｒｉｎ Ｄｉｓｃｏｖｅｒｙ | 肥満症及び糖尿病を含む代謝性疾患の処置に有用なカンナビノイド受容体拮抗薬／逆作動薬 |
| US9765031B2 (en) | 2012-11-13 | 2017-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| US11155521B2 (en) * | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| CN106660968B (zh) | 2014-05-09 | 2020-02-07 | 美国政府(由卫生和人类服务部的部长所代表) | 吡唑衍生物及其作为大麻素受体介体的用途 |
| EP3303325A1 (en) | 2015-06-04 | 2018-04-11 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cannabinoid receptor mediating compounds |
-
2013
- 2013-11-12 US US14/442,383 patent/US9765031B2/en active Active
- 2013-11-12 CA CA2889697A patent/CA2889697C/en active Active
- 2013-11-12 CN CN201380069389.9A patent/CN104884057B/zh active Active
- 2013-11-12 IN IN3733DEN2015 patent/IN2015DN03733A/en unknown
- 2013-11-12 JP JP2015542015A patent/JP6272626B2/ja active Active
- 2013-11-12 EP EP13802153.0A patent/EP2919779B1/en active Active
- 2013-11-12 WO PCT/US2013/069686 patent/WO2014078309A1/en active Application Filing
-
2017
- 2017-08-10 US US15/674,365 patent/US10683270B2/en active Active
- 2017-08-10 US US15/674,333 patent/US10787419B2/en active Active
-
2020
- 2020-05-08 US US16/870,093 patent/US11485709B2/en active Active
-
2022
- 2022-09-29 US US17/956,313 patent/US20230202983A1/en not_active Abandoned
-
2023
- 2023-02-10 US US18/108,264 patent/US11939297B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014078309A8 (en) | 2015-05-21 |
| US20230219896A1 (en) | 2023-07-13 |
| JP6272626B2 (ja) | 2018-01-31 |
| US11485709B2 (en) | 2022-11-01 |
| US20200331861A1 (en) | 2020-10-22 |
| CN104884057B (zh) | 2019-08-20 |
| US9765031B2 (en) | 2017-09-19 |
| US10787419B2 (en) | 2020-09-29 |
| WO2014078309A1 (en) | 2014-05-22 |
| US20180022706A1 (en) | 2018-01-25 |
| EP2919779B1 (en) | 2021-01-06 |
| CA2889697C (en) | 2023-03-14 |
| CA2889697A1 (en) | 2014-05-22 |
| EP2919779A1 (en) | 2015-09-23 |
| US20180022705A1 (en) | 2018-01-25 |
| US20160039766A1 (en) | 2016-02-11 |
| US20230202983A1 (en) | 2023-06-29 |
| CN104884057A (zh) | 2015-09-02 |
| US10683270B2 (en) | 2020-06-16 |
| US11939297B2 (en) | 2024-03-26 |
| JP2015536997A (ja) | 2015-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2023032I1 (en) | Deucravacitinib or a pharmaceutically acceptable salt thereof | |
| IN2015DN03733A (enrdf_load_stackoverflow) | ||
| NO2025034I1 (no) | Remdesivir or a pharmaceutically acceptable salt or ester thereof - forlengelse | |
| NO2021034I1 (no) | pemigatinib or a pharmaceutically acceptable salt thereof | |
| NO2022043I1 (en) | Asciminib or a pharmaceutically acceptable salt thereof, such as asciminib hydrochloride | |
| NO2021041I1 (no) | remimazolam or a pharmaceutically acceptable salt thereof | |
| NO2022010I1 (no) | ripretinib, or a pharmaceutically acceptable salt thereof | |
| EP2629786A4 (en) | COMPOSITIONS FOR THE ADMINISTRATION OF MEDICAMENTS | |
| ZA201407726B (en) | Pharmaceutical compositions for combination therapy | |
| PL2768479T3 (pl) | Zaróbki do kompozycji terapeutycznych zawierających nikotynę | |
| DK2632493T3 (da) | Lægemiddelindgivelsessammensætninger | |
| EP3082817A4 (en) | Compositions for drug administration | |
| PL2560624T3 (pl) | Formulacja terapeutyczna do zmniejszania skutków ubocznych leku | |
| IL228709A0 (en) | Dosage unit form for oral administration | |
| IN2014MN02598A (enrdf_load_stackoverflow) | ||
| SG11201501415RA (en) | Orally administered medical composition | |
| IL231485A0 (en) | Medicinal compounds are immune to interference | |
| GB201216018D0 (en) | Pharmacologically active compounds | |
| SMT201600341B (it) | Soluzione per somministrazione orale | |
| MY187718A (en) | Pharmaceutical formulations | |
| IL234363B (en) | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative | |
| EP2731605A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR RECTAL ADMINISTRATION | |
| IL229591A0 (en) | Addition of medicine | |
| SI2814473T1 (sl) | Farmacevtske sestave za kombinirano terapijo | |
| HUP1100641A2 (en) | A new diaza-benzofluoranthene derivate as drug |